The Intern At Work: Internal Medicine 264. The Rounds Table- Top 5 RCTs of 2024
Dec 28, 2024
Drs. Mike and John Fralick dive into the top randomized controlled trials of 2024. They highlight finerenone’s impact on heart failure outcomes and discuss innovative uses of tirzepatide for obstructive sleep apnea and liver conditions. Semaglutide’s positive effects on kidney health in diabetes patients also takes center stage. The hosts review findings on antibiotic durations for bloodstream infections, revealing shorter treatment might be just as effective. They wrap up with thoughts on the importance of credible data and community engagement.
AI Snips
Chapters
Transcript
Episode notes
Finerenone for Heart Failure
- Finerenone significantly reduces morbidity and mortality in heart failure patients with preserved ejection fraction.
- This is a game-changer for heart failure treatment, especially for those not benefiting from spironolactone.
Tirzepatide for OSA and Obesity
- Tirzepatide significantly improves obstructive sleep apnea (OSA) and obesity, even in patients already using CPAP.
- This offers a potential alternative or adjunct to CPAP therapy for OSA.
Semaglutide for Chronic Kidney Disease
- Semaglutide slows chronic kidney disease progression in type 2 diabetes patients.
- This adds another benefit to semaglutide, especially for patients with diabetes and chronic kidney disease.